Immuron Posts 6% FY26 Sales Growth, Fourth Straight Quarter of Gains
IMRN sits 76% above its 52-week low of $0.677.
Summary
Immuron reported unaudited FY26 sales of AUD$7.7 million, a 6% increase over the prior year, marking four consecutive quarters of year-over-year growth. The growth was driven by a 10% rise in Australian sales and a 7% increase in the U.S. market, partially offset by a stronger Australian dollar. The company highlighted improved digital marketing and new packaging as key drivers. This follows the strategic partnership search for its clinical assets announced in May and the completion of a small shareholder buyback in June. The sustained sales momentum in its commercial product Travelan provides a revenue base while the company seeks partners for its pipeline.
At the time of this announcement, IMRN was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.68 to $2.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.